SCHEMBL257404

SCHEMBL257404

COc1cccc(-c2cc(Cl)nc3c(-c4ccc(C)cc4)c(C)nn23)c1

nearest known ligand 0.59

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPT P10636 13/20 0.59
TDP1 Q9NUW8 1/20 0.59
MAPK1 P28482 2/20 0.57
TP53 P04637 1/20 0.50
CRHR1 P34998 1/20 0.48
KDM4E B2RXH2 2/20 0.46
CYP1A2 P05177 2/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
HIF1A Q16665 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
ALDH1A1 P00352 1/20 0.44
LMNA P02545 1/20 0.44
HPGD P15428 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
THRB P10828 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL257542 0.87 TP53 (0.55) MAPTTDP1MAPK1TP53KDM4E
SCHEMBL257698 0.85 MAPT (0.78) MAPTTDP1MAPK1TP53CRHR1
SCHEMBL15042157 0.85 TP53 (0.67) MAPTTDP1MAPK1TP53KDM4E
SCHEMBL10072008 0.84 TP53 (0.52) MAPTTDP1MAPK1TP53KDM4E
SCHEMBL15121622 0.84 MAPT (0.56) MAPTTDP1MAPK1TP53CRHR1
SCHEMBL257327 0.82 MAPT (0.58) MAPTTDP1MAPK1TP53CRHR1
SCHEMBL15121419 0.82 MAPT (0.53) MAPTTDP1MAPK1TP53CRHR1
SCHEMBL257389 0.81 MAPT (0.65) MAPTMAPK1TP53CRHR1KDM4E
SCHEMBL257701 0.81 TP53 (0.49) MAPTMAPK1TP53CYP1A2NPSR1
SCHEMBL256922 0.80 TP53 (0.65) MAPTTDP1MAPK1TP53CRHR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8975264-B2 Compound acting as a cannabinoid receptor-1 inhibitor AMOREPACIFIC CORPORATION (KR) 2015-03-10 US disclosed
US-8975264-B2 Compound acting as a cannabinoid receptor-1 inhibitor AMOREPACIFIC CORPORATION (KR) 2015-03-10 US disclosed
US-20130158025-A1 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR AMOREPACIFIC CORPORATION (KR) 2013-06-20 US disclosed
US-20130158025-A1 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR AMOREPACIFIC CORPORATION (KR) 2013-06-20 US disclosed
WO-2012030170-A2 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR (주)아모레퍼시픽 (KR) 2012-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130158025-A1 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR CNR1, CNR2, GPR18 MAPT 2617/4885TDP1 3897/4885MAPK1 519/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.